

PTO-1449 REPRODUCED ATTORNEY DOCKET NO. APPLICATION NO. 2316.2009-000 10/786,380 TION DISCLOSURE STATEMENT FIRST NAMED INVENTOR FILING DATE N AN APPLICATION Mary Jane Cardosa February 24, 2004 November 4, 2005 **EXAMINER** CONFIRMATION NO. GROUP Jse several sheets if necessary) Not Yet Assigned 3579 1642

U.S. PATENT DOCUMENTS						
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT		
MM	Al	5,185,146	02-09-1993	Altenburger, W.		
	A2	5,221,601	06-22-1993	Montagnier, et al.		
	А3	5,514,375	05-07-1996	Paoletti et al.		
	A4	5,676,950	10-14-1997	Small, Jr., et al.		
	A5	5,679,511	10-21-1997	Kwon		
	A6	5,744,140	04-28-1998	Paoletti et al.		
	A7	5,744,141	04-28-1998	Paoletti et al.		
	A8	6,440,422 B1	08-27-2002	Sutter, Gerd		
V	A9	US-2003-0035792-A1	02-20-2003	Sutter, Gerd		
				_		

EXAMINER /Mary Mosher/	DATE CONSIDERED	09/18/2006
<u> </u>		

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;582798;1

Sheet 2 of 6

				Sheet 2 of	
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION N 2316.2009-000 10/786,380				
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Mary Jane Cardosa		FILING DATE February 24	4, 2004	
November 4, 2005 (Use several sheets if necessary)	EXAMINER Not Yet Assigned	CONF 3579	IRMATION NO.	GROUP 1642	

FOREIGN PATENT DOCUMENTS						
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
MM	В1	СН 568 392	10-31-1975	Bayern Freistaat		x
	B2	EP 0 110 385 B1	02-17-1993	The United States of America		
_	В3	EP 0 198 328 B1	07-01-1992	F. Hoffmann-La Roche AG		
	B4	EP 0 324 350 A1	07-19-1989	F. Hoffmann-La Roche AG		х
	B5	WO 92/03545 A1	03-05-1992	Virogenetics Corp (US)	_	
	В6	WO 92/03545 A1 (Corrected Version)	03-05-1992	Virogenetics Corp (US)	<u>-</u>	
	В7	WO 96/40933 A1	12-19-1996	US Health (US), et al.		
	B8	WO 97/44447 A2	11-27-1997	President and Fellows of Harvard College (US)		
	В9	WO 98/13500 A2	04-02-1998	Bavarian Nordic Research Institute A/S, et al.		
\bigvee	B10	WO 99/15692 A2	04-01-1999	Bavarian Nordic Research Institute A/S, et al.		
	•					
					 	-
						-
		,				
					·	
			·			

EXAMINER /1	Mary Mosher/	DATE CONSIDERED	09/18/2006

PTO-1449 REPRODUCED	1		PPLICATION NO. 0/786,380		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Mary Jane Cardosa Filing Date February 24		1, 2004		
November 4, 2005 (Use several sheets if necessary)	EXAMINER Not Yet Assigned	CONFI 3579	RMATION NO.	GROUP 1642	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
ММ	Cı	Altenburger, W., et al., "Partial Deletion of the Human Host Range Gene in the Attenuated Vaccinia Virus MVA," Arch. Virol., 105:15-27 (1989).					
	C2	Borsani, et al., "Characterization of a Human and Murine Gene (CLCN3) Sharing Similarities to Voltage-Gated Chloride Channels and to a Yeast Integral Membrane Protein", Genomics 27:131-141 (1995).					
	C3	Bowie, et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science 257:1306-1310 (1990).					
	C4	Bray, M., et al., "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins With or Without Nonstructural Protein NS1 Are Protected Against Fatal Dengue Virus Encephaliti," J. Virol. 63(6):2853-2856 (1989).					
	C5	Cardosa, M.J., "Dengue vaccine design: issues and challenges," British Medical Bulletin, 54(2): 395-405 (1998).					
	C6	Carroll, M.W., et al., "E. Coli β-glucuronidase (GUS) as a marker for recombinant vaccinia viruses", Biotechniques, 19:352-355 (1995).					
·	C7	Chakrabarti, et al., "Vaccinia Virus Expression Vector: Coexpression of β-Galactosidase Provides Visual Screening of Recombinant Virus Plaques," Molecular and Cellular Biology 5:3403-3409 (1985).					
	C8	Chambers, T.J., et al., "Flavivirus Genome Organization, Expression, and Replication," Annu. Rev. Micorobiol. 44:649-688 (1990).					
	C9	Cruse, et al., Illustrated Dictionary of Immunology, CRC Press, Boca Raton, pages 102-103 (1995).					
	C10	Deroo, S., et al., "Antigenic and Immunogenic Phage Displayed Mimotopes as Substitute Antigens: Applications and Limitations," Combinatorial Chemistry & High Throughput Screening 4:75-110 (2001).					
	Cli	Eckels, et al., "Immunization of Monkeys with Baculovirus-Dengue Type-4 Recombinants Containing Envelope and Nonstructural Proteins: Evidence of Priming and Partial Protection", American Journal of Tropical Medicine and Hygiene 50:472-478 (1994).					
	C12	Falconar, A.K.I., et al., "Precise location of sequential dengue virus subcomplex and complex B cell epitopes on the nonstructural-1 glycoprotein," Archives of Virology, 137: 315-326(1994).					

7/1/7/70	
/Mary Mosher/	DATE CONSIDERED 09/18/2006
OPER 1	

PTO-1449 REPRODUCED			PLICATION NO. 0/786,380		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Mary Jane Cardosa Filing Date February 24,		4, 2004		
November 4, 2005 (Use several sheets if necessary)	EXAMINER Not Yet Assigned	CONF 3579	IRMATION NO.	GROUP 1642	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
MM C13		C13	Falgout, et al., "Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NS1 Protects against Lethal Dengue Virus Encephalitis," J. Virol. 64:4356-4363 (1990).				
	C14		Fonseca, BA., et al., "Recombinant Vaccinia Viruses Co-Expressing Dengue-1 Glycoproteins PreM and E Induce Neutralizing Antibodies in Mice," Vaccine 12(3):279-285 (1994).				
		C15	Greenspan, et al., "Defining Epitopes: It's not as easy as it seems," Nature Biotechnology 7:936-937 (1999).				
	C16		Gruenberg, et al., "Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains," J. Gen. Virol. 69:1391-1398 (1988).				
	C17		Hiramatsu, K., et al., "Mutational Analysis of a Neutralization Epitope on the Dengue Type 2 Virus (DEN2) Envelope Protein: Monoclonal Antibody Resistant DEN2/DEN4 Chimeras Exhibit Reduced Mouse Neurovirulence," Virology 224(2):437-445 (1996).				
	C18		Hirsch, V.M., et al., "Limited Virus Replication Following SIV Challenge of Macaques Immunized with Attenuated MVA Vaccinia Expressing SIVsm env and gag-pol," Vaccines 95, Cold Spring Harbor Laboratory Press, USA, pgs. 195-200 (1995).				
		C19	Hirsch, V.M., et al., "Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccinia Virus Ankara," J. Virol., 70(6):3741-3752 (1996).				
		C20	Henchal, E.A., et al., "Synergistic Interactions of Anti-NS1 Monoclonal Antibodies Protect Passively Immunized Mice from Lethal Challenge with Dengue 2 Virus," J. Gen. Virol. 69:2102-2107 (1988).				
		C21	Jianmin, Z., et al., "Analysis of Functional Epitopes on the Dengue 2 Envelope (E) Protein Using Monoclonal IgM Antibodies," Arch Virol. 140(5):899-913 (1995).				
		C22	Mackett, et al., "General Method for Production and Selection of Infectious Vaccinia Virus Recombinants Expressing Foreign Genes," J. Virol. 49:857-864 (1984).				
Mayr, A., et al., "The Smallpox Vaccination Strain MVA: Marker, with the Parenteral Vaccination and Behavior in Organisms with a I Bakt. Hyg., I Abt. Org. B, 167:375-390 (1978).		C23	Mayr, A., et al., "The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parenteral Vaccination and Behavior in Organisms with a Debilitated Defence Mechanism," Zbl. Bakt. Hyg., I Abt. Org. B, 167:375-390 (1978).				

			•	•
EXAMINER /Mary Mosher/	DATE CONSIDERED	09/18/2006		

PTO-1449 REPRODUCED			PLICATION NO. 0/786,380		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Mary Jane Cardosa		FILING DATE February 24, 2004		
November 4, 2005 (Use several sheets if necessary)	EXAMINER Not Yet Assigned	CONF 3579	RMATION NO.	GROUP 1642	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
М	M	C24	Mayr, A., et al., "Abstammung, Eigenschaften und Verwendung des Attenuierten Vaccinia-Stammes MVA," Infection, 3:6-14 (1975).			
		C25	Megret, et al., "Use of Recombinant Fusion Proteins and Monoclonal Antibodies to Define Linear and Discontinuous Antigenic Sites on the Dengue Virus Envelope Glycoprotein", Virology 187:480-491 (1992).			
		C26	Meyer, H., et al., "Mapping of Deletions in the Genome of the Highly Attenuated Vaccinia Virus MVA and their Influence on Virulence," J. Gen. Virol., 72:1031-1038 (1991).			
		C27	Moss, B., et al., "New mammalian expression vectors," Nature 348(6296): 91-92 (1990).			
		C28	NTIS Accession Number PB, 88201363, "Novel Recombinant Vaccinia Virus Expression Vectors and Method of Selecting Same".			
		C29	NTIS Accession Number PB89144802, "Novel Inhibitor of HIV Infection".			
		C30	NTIS Accession Number PB88192059, " A Synthetic Antigen Evoking Anti-HIV Response".			
		C31	Pupo-Antunez, Maritza et al., "Monoclonal Antibodies Raised to the Dengue-2 Virus (Cuban: A15 Strain) Which Recognize Viral Structural Proteins," Hybridoma, 16(4): 347-353 (1997).			
		C32	Scheiflinger, et al., "Evaluation of the Thymidine Kinase (TK) Locus as an Insertion Site in the Highly Attenuated Vaccinia MVA Strain," Arch. Virol. 141:663-669 (1996).			
		C33	Smucny, JJ., et al., "Murine Immunoglobulin G Subclass Responses Following Immunization With Live Dengue Virus or a Recombinant Dengue Envelope Protein," Am J. Trop Med. Hyg. 53(4):432-437 (1995).			
		C34	Stickl, H., et al., "MVA-Stufenimpfung Gegen Pocken" Disch. Med. Wschr., 99:2386-2392 (1974).			
		C35	Sutter, G., et al., "A Recombinant Vector Derived from the Host Range-Restricted and Highly Attenuated MVA Strain of Vaccinia Virus Stimulates Protective Immunity in Mice to Influenza Virus," Vaccine, 12(11):1032-1040 (1994).			
	/	C36	Sutter, G. and Moss, B., "Nonreplicating Vaccinia Vector Efficiently Expresses Recombinant Genes," Proc. Natl. Acad. Sci., USA, 89:10847-10851 (1992).			

				
EXAM	Mary Mosher/	DATE CONSIDERED	09/18/2006	
<u></u>		_i		. !

Sheet 6 of 6

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2316.2009-000 APPLICATION NO. 10/786,380		Sheet 0 of (
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION November 4, 2005 (Use several sheets if necessary)	FIRST NAMED INVENTOR Mary Jane Cardosa		FILING DATE February 24, 2004	
	EXAMINER Not Yet Assigned	CONFII 3579	RMATION NO.	GROUP 1642

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
MM		C37	Sutter, G., et al., "Non-Replicating Vaccinia Vector Efficiently Expresses Bacteriophage T7 RNA Polymerase," FEBS Letters 371:9-12 (1995).			
		C38	Sutter, G. and Moss, B., "Novel Vaccinia Vector Derived from the Host Range Restricted and Highly Attenuated MVA Strain of Vaccinia Virus," Dev. Biol. Stand. Basel, Karger, 84:195-200 (1995).			
		C39	Svrivastava, et al., "Mice Immunized with a Dengue Type 2 Virus E and NS1 Fusion Protein Made in Escherichia coli are Protected Against Lethal Dengue Virus Infection," Vaccine 13:1251 (1995).			
		C40	Venugopal, K., et al., "Towards a New Generation of Flavivirus Vaccines," Vaccine 12:11-20 (1994).			
		C41	Wang, S., et al., "Antibody-Enhanced Binding of Dengue-2 Virus to Human Platelets," Virology 213(1):254-257 (1995).			
		C42	Wyatt, et al., "Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells", Virol., 210:202-205 (1995).			
		C43	Zhao, et al., "Cloning Full-Length Dengue Type 4 Viral DNA Sequences: Analysis of Gene Coding for Structural Proteins," Virology 155:77-88 (1986).			
\	/	C44	Zhao, et al., "Expression of Dengue Virus Structural Proteins and Nonstructural Protein NS ₁ by a Recombinant Vaccinia Virus," J. Virol. 61:4019-4022 (1987).			

EXAMINER /Mary Mosher/	DATE CONSIDERED	09/18/2006